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Abstract: 
The increased use of HPV testing within cervical screening programmes necessarily brings about 
changes to the laboratory services which are required to support them.  A crucial element of such 
services is to demonstrate initial and ongoing quality of the test (and associated processes). In this 
review we outline some of the quality-considerations and challenges with an emphasis on the 
laboratory including assay and platform validation, internal quality control selection and strengths 
and weaknesses of external quality assurance schemes.      The influence and role of key external 
entities, including regulatory agencies, guideline-groups, programme commissioners and commercial 
providers are also discussed.    
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The transition from cytology to molecular testing for high-risk HPV for primary cervical screening 
continues apace.  Evidence for implementation is based on a number of randomised clinical trials 
and health technology assessments which indicate that a greater sensitivity, negative predictive 
value and inter-operator consistency is conferred by HR-HPV testing as a screening test compared to 
cytology.1,2 HR-HPV testing also provides the opportunity to extend the time between screening 
rounds.3  Additionally, the hypothesised quality reduction in the performance of cytology for the 
detection of significant lesions in immunised women has now been demonstrated, strengthening the 
argument for an objective test.4    
There remain several challenges with respect to implementation of HPV based primary screening 
that require consideration.  As articulated in the European guidelines for quality assurance in cervical 
cancer screening; optimal screening performance is achieved through a national approach, implicit 
in which are guidelines for training, recall & management, key performance indicators and external 
and internal quality assessment.5  Accordingly, it is important that we develop strategies that reflect 
the new era of cervical screening not least of which ensure the quality of the HPV test applied.   
For comprehensive quality monitoring; various “levels” of input are required.  Figure one illustrates 
some of the key contributions at three levels (A) the international contribution, (B) the requirements 
of the (particular) national screening programme and (C) the responsibility of the individual 
laboratory.  With respect to A, commercial platform providers drive regulatory compliance  and 
international, evidence based guidelines have and will continue to be highly influential.  Regarding B, 
National guidelines which outline performance requirements  for the test and the laboratories that 
deliver it are essential . Finally, with respect to C the laboratory itself is obliged to deliver testing of a 
quality which meets the standards in a particular programme but also those required to meet 
external accreditation bodies. In the present article, we will describe key considerations for 







 The commercial landscape  
An advantage of using commercial HPV tests (rather than home-brews) is that the associated 
regulatory “stamps” such as CE marking and/or FDA approval assure the user that certain 
performance criteria have been demonstrated.  As the process for CE marking is more rapid and less 
demanding than FDA approval, a greater number of CE marked tests exists but those that are FDA 
approved have a larger market share at least in Europe and the US.  In a review of commercially 
available HPV tests; Poljak and colleagues described “193 distinct commercial HPV tests and at least 
127 test variants available on the market in 2015.6 Certainly, there is a considerable variety in 
chemistry, platform, output and crucially, in the level of evidence associated with their application;  
indeed the authors described that 65% were not associated with any peer reviewed publication(s).  
It is therefore essential that the clinical performance of a test is clearly demonstrated for a cervical 
screening application and systems/metrics for achieving this are described in the section below.  This 
is particularly relevant for HPV tests as unlike other molecular viral assays, exquisite analytical 
sensitivity is not desirable given the high prevalence of transient infection.7,8   Notwithstanding this 
important issue, a highly competitive commercial landscape provides benefits to the user and 
programme in terms of price, options and the pace of innovation.     
International performance metrics/guidelines 
The now well established validation criteria of Meijer et al (2009) outline a system for validation of 
new HPV tests by comparison to a gold standard on which longitudinal performance for the 
detection of CIN2+ has been demonstrated.9  Requirements for inter and intra-laboratory 
reproducibility are also incorporated. In 2015 Arbyn et al undertook a systematic review to 
determine which tests fulfilled the criteria, which then numbered eight .10 
Said guidelines demonstrate how international collaboration (the authorship has input from 8 
countries) can support best practice.  However, they are not entirely comprehensive which is 
perhaps unsurprising given their age. Strict interpretation excludes assessment of assay-
performance in women under 30 and also of non-DNA based tests. However several programmes 
screen below the age of 30 and also, mRNA tests have been used for screening and disease 
management including within national  programmes.11,12  Furthermore, the criteria do not cover key 
operational aspects, including platform throughput; so an assay may theoretically fulfil the clinical 
performance  and reproducibility  criteria but not reconcile with throughput demands associated 
with primary screening.   
Finally, the guidelines do not incorporate assessment of type-specific performance although the use 
of genotyping as a triage of primary HPV infection is supported in several country-specific guidelines 
.13  The international VALidation of HPV GENotyping Tests - (VALGENT) project has several objectives, 
with one being to provide an evidence based framework for the clinical validation of HPV genotyping 
assays  - and so should be helpful in this regard.14  Thus, an update to the Meijer criteria  to better 
accommodate recent developments in HPV technologies, both pre-analytical and analytical would be 
welcome.   In the absence of this the onus on the national programme (and associated laboratories) 
to consider aspects that are not currently reflected in international guidance becomes ever more 
relevant. 
National input  
HPV platform selection and quality exercises 
Although there is global consensus that HR-HPV testing will replace cytology as a primary screening 
test, there is variation between countries as to application with respect to age range, time between 
screening rounds and triage strategies.15 National programmes should therefore create protocols 
which set out a pathway to acceptance/approval in addition to producing specifications for HPV 
platforms.  In some countries a single system is procured for the whole programme as is the case for 
the Netherlands.16 Comparatively in England, a list of approved platforms17 was created after 
internal review and assessment which incorporated a three-step process of “dry” assessment of key 
technical and analytical parameters, “wet” evalulation to ensure the assay and associated pre-
analytical platform performed as expected (in situ) and a comprehensive assessment of available 
literature on assay performance.  Oversight of the process/outputs by a specific working group co-
ordinated by the programme led to ratification of eligible assays.   
National programmes should also support test validation by resourcing exercises that confirm 
adequate laboratory performance prior to initiation of a new service and to determine adequate 
performance in view of system change, repair or release of new reagents.  This may include an inter-
laboratory assessment, as was carried out in England before the roll out of HPV testing for triage of 
low grade abnormalities and as a test of cure. Briefly, laboratories were tasked with testing a blinded 
validation panel composed of anonymised pooled specimens where a minimum agreement (87%) of 
observed vs expected HPV results (at the qualitative level) was required.  Table 1 shows overall 
performance relating to this scheme in 35 separate laboratories (2 operators per laboratory).  
Performance was reassuringly high, irrespective of platform used. 
In a similar vein in the Netherlands, the Rijksinsttuut voor Volksgenondheid en Milieu supported a 
national quality exercise prior to roll out of primary HPV testing. A panel independently created by a 
reference laboratory composed of HPV-containing cell line material(s) was tested initially to obtain a 
reference set of results based on the semi quantitative output of the assay (Ct value). This panel was 
disseminated to the relevant service laboratories with acceptable performance based on compliance 
with the reference set. 18 
 In addition to constructing and resourcing exercises to support laboratories embed a test– national 
programmes may provide advice on best practice for other quality measures.  For example, the UK 
CSP has created a guidance document on laboratory quality control and assurance for HPV testing.19  
Having guidance endorsed at the programme level can be constructive & supportive, particularly at 
the earlier stages of a significant “change” to a programme.  Such guides may also add to the public’s 
confidence in a HR HPV laboratory based  screening programme.  
Evaluation and monitoring, key performance Indicators and audit 
Setting out detailed metric(s) for comprehensive performance evaluation of HPV based programmes 
is beyond the scope of the present article and clearly, international collaboration for the creation of 
these will be helpful. This said, a key challenge in defining universal parameters relates to the 
adoption of different triage and management protocols for women with positive screening tests 
across the various programmes.15  Consequently, KPIs should be cognisant of evolving international 
guidance while also involving national, multi-disciplinary input from primary care, laboratory and 
clinical services to ensure all dimensions of the programme and patient pathway are represented.   
The current European guideline for quality assurance in cervical cancer screening 2015 (supplement) 
acknowledge the “diversity in the development of HPV primary screening protocols….”concluding 
“further work is required to develop standard monitoring tables and data input formats.5 However 
there is an acknowledgement that core parameters for determining the performance of HPV based 
screening are arguably similar to those currently used for cytology and can be grouped into 3 
elements (i) screening intensity, (ii) screening test performance and (iii) diagnostic assessment 
treatment and post treatment follow up.  Table 2 includes the 20 suggested parameters therein. .   
With respect to the “screening test performance” element a somewhat contentious area is what to 
consider as true disease.  The utility of CIN2 as a robust outcome/measure of significance has been 
questioned for some time. However as the threshold for treatment is still generally CIN2+ measures 
which rely exclusively on this outcome will continue to be used unless there is widespread change in 
clinical practice.  The recent meta-analysis by Tainio et al (2018) which details regression rate of 
CIN2+ may precipitate such a change.20 In the meantime it is clearly possible to evaluate 
performance, separately, according to both CIN2 and CIN3 outcomes and it should be noted that 
some systems work to the separate terminology of low grade or high grade squamous intraepithelial 
lesions (LSIL or HSIL). 
Audits 
Retrospective audits of invasive cancers (whether detected clinically of via screening) are 
recommended in several countries which offer cervical screening, particularly those with organised 
programmes and national registers. Stakeholder/staff education through workshops, regularly 
updated communications with FAQs and dedicated websites are fundamental to the success of any 
changes to the screening programme. Public education that ensures awareness and clarity in respect 
of the process, aims, benefits and limitations of cervical screening is essential. Audit should be 
undertaken for the purposes of education, learning, continuous service evaluation and 
improvement, quality assurance and clinical governance.  Cognisant of public opinion and patient 
preference at the prevailing time, if disclosure is considered and undertaken, it must be done in a 
sensitive manner at an appropriate time in the patient’s journey by members of a dedicated team 
that understand the principles goals and limitations of the programme  skilled in delivery of this type 
of information.   The move to HPV primary screening should not alter the requirement for such, 
although the operational aspects are likely to change.  Cytology slides can be reviewed 
retrospectively and are often kept for decades; they are also relatively compact and can be stored at 
room temperature. Comparatively, storing an aliquot of sample (to enable re-test of the HPV assay) 
requires significant biobanking capacity in addition to quality monitoring of sample stability.  A 
systematic costs to benefits analysis would be required if this approach were to be considered 
nationally.   In a recent article by Hortlund et al (2016), the authors suggested that estimation of the 
clinical sensitivity of CIN3+ could be achieved by obtaining “pre-diagnostic”  biobanked samples 
taken up to 2 years before.21  This is an interesting approach however requires suitable 
infrastructure and resource. Additionally, HPV assays (like all molecular microbiology assays) are 
validated according to a finite testing window so re-testing outside that window affects the 
credibility of the result.  
Relevant to this; in Australia, national guidance stipulated that HPV prevalence (in routinely taken 
screening samples) should remain within anticipated parameters and not exceed +/- 2 SD of this 
level.  To support this, laboratories were initially asked to work in operating batches of 2000 samples 
which should remain accessible in the service laboratory should retesting be required.  This 
constituted a considerable operational burden in terms of storage capacity and record keeping.21 
Furthermore, as geographic but nevertheless explainable differences in HPV prevalence have been 
observed within country (due to rurality, deprivation, age profile, vaccine uptake etc),23 exceeding a 
national average may trigger alarm bells whilst actually representing natural epidemiological 
phenomena.  Retesting also brings challenges particularly in screening settings where disease 
prevalence is low and where oscillation around a qualitative result can occur.24,25  It is notable that at 
time of preparation of this manuscript the requirement for Australian labs to store 2000 samples has 
since been removed. 
The role of the laboratory 
The delivery of a quality laboratory service is clearly supported by formal accreditation. 
Accreditation behoves a raft of practice (and evidence thereof) which relate to the test itself, the 
staff performing it and the environment. For the purposes of this manuscript we will focus on 
aspects of the test itself. 
Initial platform validation by the host laboratory and subsequent verification 
Even for (very) well evidenced commercially available HPV assays, there is still a requirement for the 
test laboratory to provide evidence that the assay performs in the anticipated way for all relevant 
biospecimens and that this is evidenced in an initial “validation” (sometimes referred to as 
verification) report.   The design of the validation exercise and the materials required for its 
execution could feasibly be defined by the programme or set by the laboratory who would 
communicate the results to the relevant quality group(s). There is flexibility around the size/scope of 
the validation-and a large exercise designed to replicate the power and outcomes of studies that 
have informed product regulatory approval is arguably excessive. One that takes into account the 
available literature and also incorporates a bench/wet assessment is practical.  Validation reports 
should include how success/failure is measured.     
Ongoing validation/verification is also required, at least annually, to demonstrate that the assay is 
working consistently. This can incorporate a summary of other longitudinal quality measures such as 
performance in EQA schemes and IQC.  Yearly verification should also incorporate aspects such as 
turnaround, machine down-time and supplier issues and regular minuted meetings with commercial 
suppliers can support this. Again, criteria for success and failure should be described in the report 
and exceptions/issues clearly articulated.  
 
Internal Quality Assessment (IQA) 
Internal quality assessment (IQA) represents one component of the laboratory quality monitoring 
process which can help assess uniformity/consistency of testing results, in addition to other 
laboratory quality indicators including interpretation of results, patient management 
recommendations etc.  At time of preparation of this manuscript, there are no explicit guidelines 
from accreditation agencies that indicate the amount of IQA that should be performed. One 
approach is to select a clinical sample at random which can be split into two aliquots at specimen 
reception, with the duplicate sample de-identified before processing.  However, this may be 
operationally challenging for certain media where less volume is available.  An alternative is to re-
test a previously reported clinical sample. The issue with IQA, is how to handle discrepant results, 
particularly those which would invoke a management change, particularly as the justification for a 
result change is questionable given that HPV assays do not have 100% intra-laboratory 
reproducibility, particularly around assay cut-off in samples with no underlying disease.25 The use of 
anonymised pooled material obviates some of the issues of discrepant IQA results . 
User defined control or internal quality control (IQC) 
Controls independent of those provided by the manufacturer should be included in each test run, 
referred to as internal quality controls or user defined controls they should ideally represent the 
whole process from extraction to detection and resemble the biological matrix of the sample under 
evaluation. Anonymised, pooled clinical material produced internally can be used as can material 
sourced from companies or reference laboratories/facilities. HPV containing-cell line material (and 
HPV negative cervical cancer cell lines) can be of use but may be challenging to produce/maintain in 
laboratories which exclusively provide diagnostic services.  
Currently, although HPV assays are applied at the qualitative level to inform management decisions, 
the semi-quantitative measure/output of assays can allow trending of IQCs relative to an established 
expected mean and increasingly commercial test providers offer IT capacity to allow longitudinal 
monitoring of IQC data.  Consistent monitoring of IQC performance and exception reporting should 
,as a minimum, be performed by the laboratory but there are examples where national oversee has 
been implemented.  In the Netherlands the IQC is run by each of the service laboratories with results 
overseen by an independent quality executive, supported by a national reference officer.  
There is an increasing demand for IQCs to be linked, where possible, to traceable standards. 
International standards exist for HPV 16 and 18, established by the WHO HPV LabNet and available 
via the National Institute for Biological Standards and Controls (NIBSC) which represent an 
international unit (IU).26 Standards that reflect IU for HPV types: 31,33,45 52 and 58 are also in 
development. However, these standards which contain lyophilised plasmid material were not 
designed to work with pre-analytical and extraction platforms so their inclusion as day-to-day IQC is 
not suitable.   Certainly, endeavours which can link the semi-quantitative output of an assay to an 
international unit would be helpful as this could support standardisation and a better assessment of  
inter-laboratory performance.  To this end collaboration between laboratories and accredited 
providers of quality materials will be helpful.27   
External Quality Assessment 
External quality assessment is an essential component of any clinical laboratory service and 
participation is a requirement for ISO15189:2012 and specific national accreditation bodies. There 
are several certified (to ISO17043:2010) EQA schemes available which assess laboratory proficiency 
in the detection of HR HPV nucleic acid. These were reviewed by Carozzi et al (2016) when HPV 
testing was primarily used as triage for cytology and for test of cure.28 Certified EQA schemes include 
those supplied by UK NEQAS, QCMD, WHO HPV LabNet, Instand and (College of American 
Pathologists) CAP.  
In general terms, EQA schemes relevant for molecular virology assays/laboratories are typically 
designed to assess analytical performance in individual laboratories. Analytical performance in terms 
of sensitivity and specificity is a reasonable end point for most clinical virology investigations.  
However the assessment of clinical performance through current HPV EQA schemes is challenged by 
the fact that there is no viral load correlate of clinically significant infection. Thus expectations of 
HPV EQA schemes have to be limited to the insight they give into technical performance of a 
platform/laboratory rather than clinical performance of the assay and screening process. Arguably 
clinical performance is revealed more optimally through longitudinal quality monitoring which takes 
into account results after the initial screening test.     This said HPV EQA schemes are still an 
important part of quality monitoring in that under-performance can highlight operational issues    
The optimal components of an EQA scheme for a molecular HPV test should ideally; (i) include 
representation of all 12-14 hrHPV types, individually or in pools at some point within the cycle of the 
scheme, (ii) reflect the sample collection matrix used in screening (ie cytology media or self-
collection media), (iii) be suitable for use in different nucleic acid amplification technologies 
(conventional PCR, real-time PCR, DNA array and transcription mediated amplification), (iv) have the 
ability to assess analytical performance of the assay, (v) have at least an annual distribution and (vi) 
assess the end to end process of the assay including pre-analytics, extraction (if performed) 
detection and reporting.  
At present, EQA programs use a mix of material including lyophilised cell cultures, pooled clinical 
samples and plasmid derived material. Each scheme has its strengths and limitations and no existing 
scheme fulfils all criteria described above.28 Pooled clinical samples reflect the reality of an actual 
sample more readily than plasmid, however, controlling for specific type(s) is challenging.  HPV 
containing cell lines have been incorporated into EQA schemes; these can be manipulated more 
easily than clinical samples and reflect cervical epithelia more closely than plasmids, however cell-
lines that represent all HR-HPV types are not readily available and the per cell  copy numbers of HPV 
genomes in these cell lines may be high and lack clinical comparison.  
The majority of the EQA schemes described above formally score on qualitative performance (ie 
presence or absence of HR-HPV types), however, as genotyping is increasingly incorporated into 
screening pathways this may well change. WHO Labnet scores on type specific performance but is 
not set up to evaluate the extraction element of an assay.  
It should be noted that given the variety of tests available, some assays will be more challenged by a 
particular EQA scheme than others. The nature of pooled, clinically derived material makes it more 
reconcilable to assays that involve target amplification by PCR and although we describe optimal 
elements of an EQA scheme, one that proves perfect for all platforms may prove lofty particularly 
given the pace of change in HPV test developments.   
Endogenous controls and interpretation 
Endogenous controls frequently involve the amplification of a housekeeping gene present in every 
human cell such as beta-globin and control for extraction and inhibition. At present, several 
molecular diagnostic assays for HPV do contain an internal control, and this aspect may be 
mandated by a particular programme. While endogenous controls can be helpful, they do not 
confirm that relevant cervical cells are necessarily in the sample, just that human cells are.  A 
positive aspect is that they guard against the possibility of media-only false negatives where, in 
error, a sample has not been taken.  The magnitude of this issue is questionable, however, and work 
is ongoing within the UK screening programme to quantify it more precisely.  It is also worth 
reflecting on the fact that most frequently used (to date) gold standard reference/comparator assay 
as detailed in Meijer 2009 guidelines described above did not contain an endogenous control, 
although this may  reflect the vintage  of the gold standard assay used therein.9  It is feasible that the 
issue of acellular samples may be higher in a self-taken component and audits and research that 
consider this will be of value, particularly as the use of self-sampling is likely to increase.29,30 
 
Discussion 
The move from cytology based screening to molecular HPV testing has necessitated a steep learning 
curve for national screening programmes and the laboratories that support them.  Our aim was to 
outline key processes and resources that can support quality assurance in addition to some of the 
current limitations of existing processes.   
National guidance on recommended platform, metrics for validation/verification and quality 
monitoring can support laboratories and may be particularly apposite at the “start” of an HPV based 
programme.  How extensively the guidance is applied will be dependent on setting and influenced 
heavily by whether a programme is organised or opportunistic.  In addition some aspects of quality 
monitoring (such as trending internal quality controls) will be harder to achieve in programmes 
where more than one HPV test platform is used.   A practically achievable and robust quality 
framework should incorporate a system which ensures monitoring of operational, analytical and 
clinical performance through its constituent and varied parts, rather than expecting a particular 
aspect (whether it be IQC, IQA, EQA) to satisfy all of the above.   Quality monitoring of a programme 
must crucially be built around protection against cancer which necessitates longitudinal assessment 
against relevant disease endpoints.  Such monitoring should also be reactive to – and take into 
account - influencing factors including vaccination.    
There is an opportunity and perhaps an obligation to learn from each other’s experience through 
national and international laboratory networks such as WHO Labnet and other forums which benefit 
from the interdisciplinary input of clinical virology, cancer screening and molecular pathology.   This 
is particularly relevant given the skill mix of laboratories that ultimately deliver the service.  
Knowledge gaps may exist within microbiology laboratories (with respect to contextualisation of the 
results for cervical screening) and cyto-pathology laboratories (with respect to high-throughput 
molecular testing and associated processes). The meeting of the International Papillomavirus Society 
and the European Organisation of Genital Infections and Neoplasia benefit from representation of 
those with laboratory, clinical, screening and molecular biology expertise and specific sessions 
dedicated to quality challenges and monitoring of HPV based programmes - with outputs that could 
be disseminated to the community -  would be of value.  Information from countries which have 
moved to full roll out of HPV screening and who have the ability, increasingly to determine the 
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